NCT00835497View on ClinicalTrials.gov

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
Healthy
Interventions
DRUG

5 mg/500 mg Glipizide Metformin Hydrochloride Tablets

1 x 5 mg/500 mg, single-dose fasting

DRUG

5 mg/500 mg METAGLIP™ Tablets

1 x 5 mg/500 mg, single-dose fasting

Trial Locations (2)

56721

PRACS Institute Ltd., East Grand Forks

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00835497 - 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting | Biotech Hunter | Biotech Hunter